

# Bishal Gyawali

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1170355/publications.pdf>

Version: 2024-02-01

219  
papers

6,382  
citations

136885

32  
h-index

85498

71  
g-index

224  
all docs

224  
docs citations

224  
times ranked

11988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	3.4	1,260
2	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
3	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
4	Breast cancer early detection: A phased approach to implementation. <i>Cancer</i> , 2020, 126, 2379-2393.	2.0	261
5	Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. <i>JAMA Internal Medicine</i> , 2019, 179, 906.	2.6	189
6	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	3.4	130
7	Prevalence of Hypertension in Member Countries of South Asian Association for Regional Cooperation (SAARC). <i>Medicine (United States)</i> , 2014, 93, e74.	0.4	127
8	Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l5221.	2.4	117
9	Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. <i>EClinicalMedicine</i> , 2020, 20, 100269.	3.2	102
10	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. <i>JAMA Oncology</i> , 2021, 7, 728.	3.4	94
11	ReDO_DB: the repurposing drugs in oncology database. <i>Ecancermedicalsecience</i> , 2018, 12, 886.	0.6	86
12	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. <i>JAMA Oncology</i> , 2021, 7, 379.	3.4	81
13	Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. <i>EClinicalMedicine</i> , 2020, 21, 100332.	3.2	80
14	Immunotherapy in Nonâ€“Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1863-1867.	0.8	76
15	Efficacy, Safety, and Regulatory Approval of Food and Drug Administrationâ€“Designated Breakthrough and Nonbreakthrough Cancer Medicines. <i>Journal of Clinical Oncology</i> , 2018, 36, 1805-1812.	0.8	72
16	Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. <i>Oncology Reports</i> , 2016, 35, 1727-1731.	1.2	71
17	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. <i>Lancet Oncology, The</i> , 2021, 22, 1367-1377.	5.1	69
18	Prevalence of type 2 diabetes in Nepal: a systematic review and meta-analysis from 2000 to 2014. <i>Global Health Action</i> , 2015, 8, 29088.	0.7	63

#	ARTICLE	IF	CITATIONS
19	Association between progression-free survival and patients' quality of life in cancer clinical trials. <i>International Journal of Cancer</i> , 2019, 144, 1746-1751.	2.3	62
20	An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e1-e12.	1.8	62
21	Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 492-494.	13.9	48
22	Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 60, 18-23.	3.4	48
23	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors. <i>JAMA Network Open</i> , 2018, 1, e180416.	2.8	45
24	Muscle wasting associated with the long-term use of mTOR inhibitors. <i>Molecular and Clinical Oncology</i> , 2016, 5, 641-646.	0.4	41
25	Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. <i>BMJ, The</i> , 2021, 374, n1959.	3.0	40
26	Economics of Cancer Medicines: For Whose Benefit?. <i>New Bioethics</i> , 2017, 23, 95-104.	0.5	39
27	Burden of Diabetes and Prediabetes in Nepal: A Systematic Review and Meta-Analysis. <i>Diabetes Therapy</i> , 2020, 11, 1935-1946.	1.2	39
28	Combating non-communicable diseases: potentials and challenges for community health workers in a digital age, a narrative review of the literature. <i>Health Policy and Planning</i> , 2019, 34, 55-66.	1.0	38
29	Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 103-109.	1.1	38
30	Awareness, prevalence, treatment, and control of type 2 diabetes in a semi-urban area of Nepal: Findings from a cross-sectional study conducted as a part of COBIN-D trial. <i>PLoS ONE</i> , 2018, 13, e0206491.	1.1	37
31	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	2.0	37
32	Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1288-1294.	1.3	36
33	Challenges in diabetes mellitus type 2 management in Nepal: a literature review. <i>Global Health Action</i> , 2016, 9, 31704.	0.7	35
34	COVID-19 and cancer: do we really know what we think we know?. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 386-388.	12.5	35
35	Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway. <i>JAMA Internal Medicine</i> , 2021, 181, 1275.	2.6	34
36	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. <i>Oncologist</i> , 2019, 24, e397-e399.	1.9	33

#	ARTICLE	IF	CITATIONS
37	Chemotherapy in locally advanced head and neck squamous cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 44, 10-16.	3.4	32
38	Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	32
39	Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. <i>EClinicalMedicine</i> , 2020, 23, 100403.	3.2	32
40	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. <i>JAMA Internal Medicine</i> , 2021, 181, 490.	2.6	32
41	A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. <i>Ecancermedalscience</i> , 2018, 12, 847.	0.6	31
42	Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment. <i>Annals of Oncology</i> , 2019, 30, 96-102.	0.6	30
43	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	2.6	30
44	Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. <i>JAMA Internal Medicine</i> , 2021, 181, 499.	2.6	28
45	Ischemic Stroke and Impact of Thyroid Profile at Presentation: A Systematic Review and Meta-analysis of Observational Studies. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2926-2934.	0.7	27
46	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.	2.8	27
47	Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. <i>JCO Global Oncology</i> , 2020, 6, 1211-1217.	0.8	26
48	Prevalence and correlates of psychological distress symptoms among patients with substance use disorders in drug rehabilitation centers in urban Nepal: a cross-sectional study. <i>BMC Psychiatry</i> , 2016, 16, 314.	1.1	25
49	Drugs that lack single-agent activity: are they worth pursuing in combination?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 193-194.	12.5	25
50	Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials. <i>Annals of Oncology</i> , 2017, 28, 898-899.	0.6	24
51	Cancer groundshot: going global before going to the moon. <i>Lancet Oncology</i> , The, 2018, 19, 288-290.	5.1	24
52	Real-world evidence and regulatory drug approval. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 271-272.	12.5	24
53	Progression-free survival: it is time for a new name. <i>Lancet Oncology</i> , The, 2022, 23, 328-330.	5.1	24
54	Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. <i>Journal of Global Oncology</i> , 2017, 3, 93-97.	0.5	23

#	ARTICLE	IF	CITATIONS
55	Reporting harms more transparently in trials of cancer drugs. <i>BMJ: British Medical Journal</i> , 2018, 363, k4383.	2.4	23
56	Reinforcing the social compromise of accelerated approval. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 596-597.	12.5	23
57	Opioid-induced constipation. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1331-1338.	0.6	22
58	Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	22
59	Diabetes management training for female community health volunteers in Western Nepal: an implementation experience. <i>BMC Public Health</i> , 2018, 18, 641.	1.2	22
60	Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics. <i>Journal of Clinical Oncology</i> , 2021, 39, 175-177.	0.8	22
61	Health System Preparedness for COVID-19 and Its Impacts on Frontline Health-Care Workers in Nepal: A Qualitative Study Among Frontline Health-Care Workers and Policy-Makers. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, 16, 2560-2568.	0.7	21
62	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 36-43.	2.3	21
63	Should low-income countries invest in breast cancer screening?. <i>Cancer Causes and Control</i> , 2016, 27, 1341-1345.	0.8	20
64	Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. <i>Annals of Oncology</i> , 2017, 28, 246-253.	0.6	19
65	Low-value practices in oncology contributing to financial toxicity. <i>Ecancermedalscience</i> , 2017, 11, 727.	0.6	19
66	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 374-387.	1.8	19
67	A systematic review and meta-analysis of non-adherence to anti-diabetic medication: Evidence from low- and middle-income countries. <i>International Journal of Clinical Practice</i> , 2021, 75, e14717.	0.8	19
68	A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries. <i>Lancet Haematology</i> , 2020, 7, e638-e639.	2.2	18
69	Challenges and opportunities for cancer clinical trials in low- and middle-income countries. <i>Nature Cancer</i> , 2020, 1, 142-145.	5.7	18
70	Me-too drugs with limited benefits – the tale of regorafenib for HCC. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 653-654.	12.5	17
71	The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer. <i>JAMA Oncology</i> , 2018, 4, 623.	3.4	17
72	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. <i>BMJ Open</i> , 2019, 9, e033728.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report. <i>Oncology Letters</i> , 2015, 10, 972-974.	0.8	16
74	Combining drugs and extending treatment – a PFS end point is not sufficient. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 521-522.	12.5	16
75	Cardio-metabolic disease risk factors among South Asian labour migrants to the Middle East: a scoping review and policy analysis. <i>Globalization and Health</i> , 2019, 15, 33.	2.4	16
76	A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. <i>Journal of the National Cancer Institute</i> , 2020, 112, 335-342.	3.0	16
77	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 1455-1462.	2.3	16
78	Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Global Oncology</i> , 2016, 2, 145-153.	0.5	15
79	Is the number of cancer drug approvals a surrogate for regulatory success?. <i>Journal of Cancer Policy</i> , 2019, 22, 100202.	0.6	15
80	Community-based interventions for prevention of Type 2 diabetes in low- and middle-income countries: a systematic review. <i>Health Promotion International</i> , 2019, 34, 1218-1230.	0.9	15
81	Prevalence of American Heart Association defined ideal cardiovascular health metrics in Nepal: findings from a nationally representative cross-sectional study. <i>International Health</i> , 2020, 12, 325-331.	0.8	15
82	Application of single-level and multi-level modeling approach to examine geographic and socioeconomic variation in underweight, overweight and obesity in Nepal: findings from NDHS 2016. <i>Scientific Reports</i> , 2020, 10, 2406.	1.6	15
83	Effectiveness of a Female Community Health Volunteer-Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2021, 4, e2035799.	2.8	15
84	Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. <i>Oncologist</i> , 2018, 23, 367-374.	1.9	14
85	Community-based intervention for management of diabetes in Nepal (COBIN-D trial): study protocol for a cluster-randomized controlled trial. <i>Trials</i> , 2018, 19, 579.	0.7	14
86	Making adjuvant therapy decisions with uncertain data. <i>Annals of Oncology</i> , 2019, 30, 361-364.	0.6	14
87	Covid-19 Pandemic – An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?. <i>JAMA Oncology</i> , 2020, 6, 1693.	3.4	14
88	Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. <i>Seminars in Oncology</i> , 2021, 48, 141-144.	0.8	14
89	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	2.6	14
90	Cancer treatments should benefit patients: a common-sense revolution in oncology. <i>Nature Medicine</i> , 2022, 28, 617-620.	15.2	14

#	ARTICLE	IF	CITATIONS
91	Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. <i>JAMA Oncology</i> , 2022, 8, 879.	3.4	14
92	Me, Too. <i>Journal of Global Oncology</i> , 2016, 2, 99-104.	0.5	13
93	Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs. <i>JAMA Network Open</i> , 2019, 2, e199570.	2.8	13
94	Barriers and facilitators to cervical cancer screening uptake among women in Nepal – a qualitative study. <i>Women and Health</i> , 2020, 60, 963-974.	0.4	13
95	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. <i>JCO Oncology Practice</i> , 2022, 18, e1164-e1169.	1.4	13
96	Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 859-862.	2.3	12
97	Does global oncology need artificial intelligence?. <i>Lancet Oncology</i> , The, 2018, 19, 599-600.	5.1	12
98	Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky016.	1.4	12
99	Building Strong Primary Health Care to Tackle the Growing Burden of Non-Communicable Diseases in Nepal. <i>Global Health Action</i> , 2020, 13, 1788262.	0.7	12
100	Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got. <i>JAMA Oncology</i> , 2021, 7, 677.	3.4	12
101	Pemetrexed in Nonsquamous Non–Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 17.	3.4	11
102	Association between age and sex and mortality after adjuvant therapy for renal cancer. <i>Cancer</i> , 2019, 125, 1637-1644.	2.0	11
103	Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma. <i>JAMA Oncology</i> , 2020, 6, 296.	3.4	11
104	Human Trafficking in Nepal: Post-Earthquake Risk and Response. <i>Disaster Medicine and Public Health Preparedness</i> , 2017, 11, 153-154.	0.7	10
105	Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?. <i>International Journal of Cancer</i> , 2018, 143, 2079-2081.	2.3	10
106	The burden and correlates of multiple cardiometabolic risk factors in a semi-urban population of Nepal: a community-based cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 15382.	1.6	10
107	Does <i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer increase all-cause mortality?. <i>International Journal of Cancer</i> , 2019, 144, 411-412.	2.3	10
108	Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. <i>EClinicalMedicine</i> , 2020, 25, 100458.	3.2	10

#	ARTICLE	IF	CITATIONS
109	Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic. JCO Global Oncology, 2020, 6, 1490-1493.	0.8	10
110	Rethinking community based strategies to tackle health inequities in South Asia. BMJ: British Medical Journal, 2018, 363, k4884.	2.4	9
111	Duration of adjuvant immunotherapyâ€”biologic, clinical and economic considerations. Medical Oncology, 2018, 35, 160.	1.2	9
112	Challenges and Opportunities for Biomarker Validation. Journal of Law, Medicine and Ethics, 2019, 47, 357-361.	0.4	9
113	The promise of ESCAT: a new system for evaluating cancer drugâ€”target pairs. Nature Reviews Clinical Oncology, 2019, 16, 147-148.	12.5	9
114	A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. EClinicalMedicine, 2021, 32, 100730.	3.2	9
115	Epidemiologic Pattern of Cancer in Kathmandu Valley, Nepal: Findings of Population-Based Cancer Registry, 2018. JCO Global Oncology, 2021, 7, 443-452.	0.8	9
116	Risk-Stratifying Treatment Strategies for Febrile Neutropeniaâ€”Tools, Tools Everywhere, and Not a Single One That Works?. JCO Oncology Practice, 2021, 17, OP.21.00148.	1.4	9
117	Oncology training programmes for general practitioners: a scoping review. Ecancermedalscience, 2021, 15, 1241.	0.6	9
118	Does the oncology community have a rejection bias when it comes to repurposed drugs?. Ecancermedalscience, 2018, 12, ed76.	0.6	9
119	Trends in drug revenue among major pharmaceutical companies: A 2010â€”2019 cohort study. Cancer, 2022, 128, 311-316.	2.0	9
120	Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs. The Lancet Regional Health Americas, 2022, 7, 100157.	1.5	9
121	Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncology, The, 2022, 23, 201-203.	5.1	9
122	Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?. Journal of Clinical Oncology, 2022, 40, 1518-1521.	0.8	9
123	Atezolizumab in Metastatic Triple-Negative Breast Cancerâ€”No Contradiction in the Eyes of a Dispassionate Observer. JAMA Oncology, 2021, 7, 1285.	3.4	8
124	Cervical cancer screening in Nepal: ethical considerations. Medicolegal and Bioethics, 0, , 1.	1.7	7
125	Negative trials in ovarian cancer: is there such a thing as too much optimism?. Ecancermedalscience, 2016, 10, ed58.	0.6	7
126	Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. Critical Reviews in Oncology/Hematology, 2016, 102, 118-124.	2.0	7



#	ARTICLE	IF	CITATIONS
127	The OlympiAD trial: who won the gold?. <i>Ecancermedalscience</i> , 2017, 11, ed75.	0.6	7
128	Cancer drugs in LMICs: cheap but unaffordable. <i>Oncotarget</i> , 2017, 8, 89425-89426.	0.8	7
129	Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
130	May Measurement Month 2017: an analysis of blood pressure screening results in Nepal—South Asia. <i>European Heart Journal Supplements</i> , 2019, 21, D83-D85.	0.0	7
131	US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 607.	3.4	7
132	Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer—Either, Both, or Neither?. <i>JAMA Oncology</i> , 2019, 5, 148.	3.4	7
133	Text Messaging in Cancer-Supportive Care: A Systematic Review. <i>Cancers</i> , 2021, 13, 3542.	1.7	7
134	Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura. <i>Journal of the Nepal Medical Association</i> , 2016, 55, 16-21.	0.1	7
135	Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. <i>Ecancermedalscience</i> , 2020, 14, 1091.	0.6	7
136	Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians. <i>Journal of Palliative Medicine</i> , 2015, 18, 977-980.	0.6	6
137	Some Questions on the Randomized Controlled Trial of Communication Skills Training for Oncologists. <i>Journal of Clinical Oncology</i> , 2015, 33, 222-222.	0.8	6
138	Same Data; Different Interpretations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3729-3732.	0.8	6
139	Cancer treatment in the last 6 months of life: when inaction can outperform action. <i>Ecancermedalscience</i> , 2018, 12, 826.	0.6	6
140	Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival. <i>JAMA Network Open</i> , 2019, 2, e193684.	2.8	6
141	Fall in US cancer death rates: Time to pop the champagne?. <i>EClinicalMedicine</i> , 2020, 19, 100279.	3.2	6
142	First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. <i>JCO Oncology Practice</i> , 2021, 17, e1537-e1550.	1.4	6
143	Knowledge, attitude, preventive practices and utilization of cervical cancer screening among women in Nepal: a community-based cross-sectional study. <i>European Journal of Cancer Prevention</i> , 2022, 31, 73-81.	0.6	6
144	Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. <i>Targeted Oncology</i> , 2021, 16, 415-424.	1.7	6

#	ARTICLE	IF	CITATIONS
145	Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1258-1263.	2.3	6
146	Not an "either/or": Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response. <i>Journal of Global Health</i> , 2021, 11, 03119.	1.2	6
147	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	0.8	6
148	TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. <i>ESMO Open</i> , 2016, 1, e000058.	2.0	5
149	What Global Oncology Needs: Mutual Learning and More Funding. <i>Journal of Global Oncology</i> , 2018, 4, 1-3.	0.5	5
150	Low levels of ideal cardiovascular health in a semi-urban population of Western Nepal: a population-based, cross-sectional study. <i>Heart Asia</i> , 2019, 11, e011131.	1.1	5
151	Pesticide exposure and diabetes mellitus in a semi-urban Nepali population: a cross-sectional study. <i>International Archives of Occupational and Environmental Health</i> , 2020, 93, 513-524.	1.1	5
152	Risk of COVID-19 in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 1471.	3.4	5
153	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets. <i>Journal of Cancer Policy</i> , 2021, 28, 100283.	0.6	5
154	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021, 150, 203-210.	1.3	5
155	Effective approaches to improve the psychosocial work environment. <i>International Journal of Medical Science and Public Health</i> , 2015, 4, 1.	0.2	5
156	Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber. <i>Ecancermedicalsecience</i> , 2020, 14, ed104.	0.6	5
157	Should the control arms of randomized trials have an expiry date?. <i>Nature Reviews Clinical Oncology</i> , 2022, , .	12.5	5
158	Cancer care and research in India: what does it mean to Nepal?. <i>Lancet Oncology, The</i> , 2014, 15, e299-e300.	5.1	4
159	Meta-analyses and RCTs in oncology—what is the right balance?. <i>Lancet Oncology, The</i> , 2018, 19, 1565-1566.	5.1	4
160	FDA approval standards for anticancer agents—lessons from two recent approvals in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 397-398.	12.5	4
161	Differences in cancer incidence and pattern between urban and rural Nepal: one-year experience from two population-based cancer registries. <i>Ecancermedicalsecience</i> , 2021, 15, 1229.	0.6	4
162	Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	4

#	ARTICLE	IF	CITATIONS
163	Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber. <i>Ecancermedicalscience</i> , 2020, 14, ed104.	0.6	4
164	Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. <i>European Journal of Cancer</i> , 2022, , .	1.3	4
165	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	4
166	Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal. <i>British Journal of Haematology</i> , 2016, 173, 941-942.	1.2	3
167	Use of donated clotting factors for surgeries on haemophilic patients in a resourceâ€constrained country: a kind donor, good outcome, change of practice and future directions. <i>Haemophilia</i> , 2016, 22, e453-5.	1.0	3
168	Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Nonâ€Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 691-692.	0.8	3
169	Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. <i>Future Oncology</i> , 2017, 13, 935-944.	1.1	3
170	Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 100-115.	1.8	3
171	Aumolertinib in <i>EGFR</i>-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease <i>Access</i>?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3103-3105.	0.8	3
172	Discordance between the results and conclusions of ICON7. <i>Lancet Oncology</i> , The, 2015, 16, e478.	5.1	2
173	Lung Cancer Survival Gains: Contributions of Academia and Industry. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 465-467.	0.4	2
174	Clinical Trial End Points in Severe COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1578-1580.	1.4	2
175	Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6573-6573.	0.8	2
176	Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.. <i>Journal of Clinical Oncology</i> , 2019, 37, 395-395.	0.8	2
177	Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2071-2071.	0.8	2
178	Mismatch between mortality burden and number of FDA registration trials in highly lethal cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2072-2072.	0.8	2
179	Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptorâ€Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e224361.	2.8	2
180	Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. <i>JCO Global Oncology</i> , 2022, , .	0.8	2

#	ARTICLE	IF	CITATIONS
181	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. <i>JCO Global Oncology</i> , 2022, , .	0.8	2
182	Survival of patients with metastatic breast cancer with or without locoregional therapy. <i>Lancet Oncology</i> , The, 2015, 16, e586.	5.1	1
183	Flaws in the trial design of IFCT-0802. <i>Annals of Oncology</i> , 2015, 26, 2003.	0.6	1
184	Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries. <i>Leukemia and Lymphoma</i> , 2016, 57, 474-476.	0.6	1
185	FDA Approval Summary: Sonidegibâ€”Letter. <i>Clinical Cancer Research</i> , 2017, 23, 5993-5993.	3.2	1
186	Causes, Consequences, and Control of High Cancer Drug Prices. , 2019, , 39-57.		1
187	Gender differences in outcomes of cancer patients with COVID: Signal or noise?. <i>EClinicalMedicine</i> , 2020, 26, 100535.	3.2	1
188	Evaluating Vitamin D levels in Rheumatic Heart Disease patients and matched controls: A case-control study from Nepal. <i>PLoS ONE</i> , 2020, 15, e0237924.	1.1	1
189	When Is a Suboptimal Approach to Cancer Screening Better Than None?. <i>AMA Journal of Ethics</i> , 2020, 22, E93-101.	0.4	1
190	The need for locally generated data in haematology: a realâ€”world experience of aplastic anaemia in Nepal. <i>British Journal of Haematology</i> , 2021, 192, e63-e65.	1.2	1
191	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. <i>Current Oncology</i> , 2021, 28, 1518-1527.	0.9	1
192	Disparities in the availability of and access to antiemetics recommended by the international antiemetic guidelines in Serbia, Japan, and Nepal.. <i>Journal of Clinical Oncology</i> , 2016, 34, 117-117.	0.8	1
193	Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. <i>Ecancermedicalscience</i> , 2021, 15, 1301.	0.6	1
194	Radiographic progression-free survival in the ACIS trial for prostate cancer. <i>Lancet Oncology</i> , The, 2022, 23, e4.	5.1	1
195	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. <i>Current Oncology</i> , 2022, 29, 2530-2538.	0.9	1
196	Biosimilars in oncology: everybody agrees but nobody uses?. <i>Recenti Progressi in Medicina</i> , 2017, 108, 172-174.	0.8	1
197	Training General Practitioners in Oncology: A Needs Assessment Survey From Nepal. <i>JCO Global Oncology</i> , 2022, , .	0.8	1
198	Loss of muscle mass associated with the long term use of mTOR inhibitors. <i>Annals of Oncology</i> , 2016, 27, vii87.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Geriatric assessment for the evaluation of tolerability to out-patient chemotherapy among elderly cancer patients. <i>Annals of Oncology</i> , 2016, 27, vii61.	0.6	0
200	MPS 06-07 INDOOR USE OF SOLID BIOMASS FUEL AND INCREASES IN BLOOD PRESSURE IN THE MUNICIPALITY OF LEKHNATH, NEPAL. <i>Journal of Hypertension</i> , 2016, 34, e95.	0.3	0
201	Rushing will not help to choose the best combination. <i>Lancet Oncology</i> , The, 2017, 18, e186.	5.1	0
202	A2070 The prevalence and burden of multiple cardio metabolic risk factors in semi-urban population in Nepal. <i>Journal of Hypertension</i> , 2018, 36, e19.	0.3	0
203	A2780 Association between body mass index among children aged 10â€“15 years and socio-economic status of their household in selected schools of Lekhnath, Nepal. <i>Journal of Hypertension</i> , 2018, 36, e282.	0.3	0
204	A3811 Low levels of ideal cardiovascular health among adults in a semi-urban area of Western Nepal. <i>Journal of Hypertension</i> , 2018, 36, e127.	0.3	0
205	Information Transparency in the Drug Approval Processâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 1622.	3.4	0
206	Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016. <i>Ecanermedalscience</i> , 2016, 10, ed59.	0.6	0
207	The incidence and risks of adverse events in randomized controlled trials (RCTs) of cancer drugs downplaying the harms.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14036-e14036.	0.8	0
208	A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22128-e22128.	0.8	0
209	Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 760-762.	2.3	0
210	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19303-e19303.	0.8	0
211	Community-based management of chronic obstructive pulmonary disease in Nepalâ€”Designing and implementing a training program for Female Community Health Volunteers. <i>PLOS Global Public Health</i> , 2022, 2, e0000253.	0.5	0
212	Title is missing!. , 2020, 15, e0237924.		0
213	Title is missing!. , 2020, 15, e0237924.		0
214	Title is missing!. , 2020, 15, e0237924.		0
215	Title is missing!. , 2020, 15, e0237924.		0
216	Title is missing!. , 2020, 15, e0237924.		0

#	ARTICLE	IF	CITATIONS
217	Title is missing!. , 2020, 15, e0237924.		0
218	A needs assessment survey to inform a general practitioner in oncology (GPO) training program in Nepal.. Journal of Clinical Oncology, 2022, 40, 11024-11024.	0.8	0
219	Globalization of oncology clinical trials: Which lower-middle and upper-middle income countries are participating?. Journal of Clinical Oncology, 2022, 40, e13512-e13512.	0.8	0